INTRODUCTION
The technology for producing monoclonal antibodies (MAbs), which has developed over the past fifteen years, has revolutionised many areas of the biological sciences. In the last five years, there has been an explosion of work whereby MAbs have been produced and characterised against thousands of antigens. Without such MAb reagents, many recent advances in science would have been impossible. The property which makes MAbs so useful as reagents is their single molecular structure. Single cells producing antibody are selected and cloned, eventually producing a population of cells which secrete an identical antibody. The antibody is homogeneous, in that the paratopes (combining sites) which bind to the eliciting epitope (antigenic site) are identical. Figure 1 , which compares MAbs to polyclonal antibodies, illustrates this point.
The methods used to clone and produce MAbs are not dealt with in this paper; readers are referred to a paper on the subject written by A.M. Campbell (1) . The facilities required to produce MAbs are not particularly specialised, and MAbs can be produced by any laboratory which can perform tissue culture.
Although the production of MAbs is now almost routine due to the supply of myeloma cell-lines and the level of technological advances, one should remember that considerable effort and resources are required for the characterisation and maintenance of MAbs. As this is time-consuming and costly, due consideration should be given to the 
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likely value of MAbs, if obtained. This also includes examination of the literature for possible availability of MAbs able to perform the "task" required. There is a natural and understandable tendency for scientists to want to do everything themselves. This is admirable but can lead to valuable time being lost, especially where resources are limited, e.g. in less developed countries. Workers involved in producing and characterising MAbs need to standardise the reporting of MAb reactions (types of assays used, concentrations, etc.), in order to allow other scientists to evaluate reagents. This is particularly relevant when considering the use of MAbs for diagnosis.
CENTRAL ROLE OF MONOCLONAL ANTIBODIES
A common theme for biologists is the examination of the differences between disease agents and the relation of these differences with functional properties which may be relevant to the interaction of the disease agents with the target host. Ultimately, all such properties result from the exact chemical nature of disease agents and their target. MAbs have a unique property which allows investigation of the molecular nature of epitopes when assessed in conjunction with other test data; once the reactivity of MAbs has been defined at the chemical level, they can be used as powerful tools in sensitive, specific and rapid tests. Thus, MAbs offer a link between chemical structure and antigenic and immunogenic properties, as shown in Figure 2 . 
The linking properties of monoclonal antibodies (MAbs)
The characterisation and the use of MAbs to examine the molecular properties of disease agents will be illustrated with reference to studies on foot and mouth disease (FMD) viruses. These viruses cause an economically important disease and have been studied intensely at the serological and molecular level with the object of improving FMD control through the production of better vaccines. FMD viruses belong to the family Picornaviridae (small viruses containing a single-stranded ribonucleic acid [RNA] ) and have been placed in a group called Aphthoviridae, which is characterised by acid lability (viruses disintegrate at pHs below 6.8). The group has seven serotypes: O, A, C, SAT1, SAT2, SAT3 and Asia 1 (SAT denotes "South African Territory"). Animals which have been infected or vaccinated by a virus from one serotype generally remain immune against the same type but are not immune against the others. However, viruses have been found to occur in nature which can overcome protection conferred by antibodies of the same serotype. This is a result of selection of antigenically-different mutants produced under a variety of scenarios in the field. Such viruses are sufficiently different to avoid protective humoral antibody which has been induced after infection or vaccination with the original member of the serotype. Variation can also be identified in the laboratory through passage in different tissue culture cells or laboratory animals; the identification of such variation can be important in the selection and production of vaccine strains. The need to study antigenic variation at all levels has led to the production of MAbs against various isolates, since polyclonal antisera have limited Sources of variation in antigens to foot and mouth disease viruses ability to distinguish between antigens which do not differ greatly. Figure 3 shows the possible sources of variation of FMD viruses for which rapid characterisation is important, and there is an epidemiological need for rapid identification of isolates.
Approach to using MAbs in studies on FMD viruses
FMD viruses have a relatively simple structure, with an outer capsid protein coat surrounding a single-stranded RNA molecule. They are relatively small (25-30 nm in diameter), compared to an immunoglobulin (Ig)G molecule, for example, which is approximately 12 nm long and the combining sites (fragment antigen binding [FAB] ) of which can span approximately 15 nm (optimum of 10 nm). The relative size of antibodies to a disease agent should always be assessed, since this has important consequences in analysing binding data. The capsid is composed of three proteins of equal weight: VP1, VP2 and VP3. The proteins are composed of amino acids which fold and interweave to produce a regular structure. There are regions on the surface of the capsid which are noted as being hypervariable and associated with immunogenic properties. The sequencing of the proteins from different viruses within a serotype and identification of the amino acid residues has shown that amino acid sequence variation is located in similar regions associated with externally-sited amino acids. Such, information has been confirmed recently by the spectacular visualisation of the capsid by X-ray crystallography. However, before this confirmation, a great deal of information about the nature of antigenic sites was obtained by the use of MAbs against FMD viruses in combination with sequencing studies. Such studies are described below in order to illustrate useful approaches.
MAbs against FMD viruses are raised in conventional ways. Usually, FMD viruses are purified and inactivated (RNA destroyed but antigenically identical) before being injected into BALB/c mice in an adjuvant, with several boosters. The mouse produces antibodies and antibody-secreting cells. Fusions are performed, whereby cells from the spleen of the antibody-producing mice are fused with mice myeloma cell-lines. Fusion takes place under defined conditions, where some cells have the properties of antibody secretion (against FMD virus) and infinite growth potential (from the myeloma). Clones are produced by a process which involves growth in media containing specific drugs and cloning of cells by limit dilution or picking of individual cells from semi-solid media (attempting to grow up a single cell from many); the cells of these clones secrete antibody into the supernatant tissue. Initially such antibodies are screened for reactivity with the FMD virus which is used to prime the mice. Screening is usually performed by immunoassay, in particular the enzyme-linked immunosorbent assay (ELISA). This assay is now a fundamental test in biology, allowing great flexibility in conditions and with a capacity for performing a large number of tests rapidly on microtitre plates. ELISA is thus greatly suited to the MAb field and is widely used.
Screening by ELISA would typically involve a system such as that shown in Figure 4 . 
Screening for monoclonal antibodies
A capture antibody is used to trap FMD virus from tissue culture. After washing away excess virus, the tissue culture supernatants from the cloned cells are applied onto the wells by pipette, having previously been diluted in a blocking buffer to prevent non specific attachment of mouse proteins to the plastic wells. After incubation and washing, any mouse antibody binding to the virus is detected by the addition of an antimouse IgG enzyme conjugate, which has also been diluted in a blocking buffer. Any specifically-reacted conjugate is detected by the addition of a substrate solution which changes colour if enzyme is present. The colour change thus signifies specific antibody reaction. Clones which are secreting anti-FMD virus antibody are noted and expanded by passage in tissue culture. At this stage, larger amounts of tissue culture fluid are available and characterisation of particular reactions of the individual MAbs can begin using a variety of tests.
In the case of FMD viruses, it was shown that the MAbs which could neutralise the virus are those which are able to discriminate between viruses within the same serotype (subtype). Other MAbs are produced against more cross-reactive sites common to all members of the serotype; in general these MAbs do not neutralise or discriminate. Thus, in trying to understand properties such as antigenic variation, MAbs are required which can show these differences. Such MAbs can then be used to locate differences on the capsid. Clones are therefore screened for neutralisation ability. This process is relatively simple, involving the titration of a virus seed (homologous virus) against sensitive cells in microtitre plates. A dilution is obtained which is approximately 50-100 times greater than that which kills 50% of a defined concentration of cells in culture (TCID50). MAbs are diluted in tissue culture medium (two-fold series) and virus (pretitrated as above) is added. After a brief incubation at 37°C to allow antibody/antigen reaction, cells in growth medium are added. The cultures are checked after incubation for two days and neutralisation is noted where no infection of cells is observed. Thus MAbs capable of neutralising virus are identified.
Further properties of these MAbs can easily be found, using a variety of antigenic preparations and ELISAs. In this way, whole virions, virions treated with trypsin, sodium dodecyl sulphate (SDS) and mercaptoethanol-treated virions (denatured) and sub-units may be examined by a variety of ELISA formats and other techniques, such as separation of polypeptides by Polyacrylamide gel electrophoresis (PAGE) and Western blotting followed by antibody binding. Such characterisation is important in the context of implications for molecular biology. Other assays are designed to examine the topographical relationship of the epitopes identified by the MAbs (whether the MAbs are reacting with the same or different geographically-located sites). These assays are usually performed using ascites fluid material. In this process, the cloned MAbs are injected into drug-treated mice, which then develop soft tumours and produce a large amount of ascites fluid which contains a high concentration of MAb (1-10 mg/ml). The usual concentration of MAb immunoglobulin in tissue culture is 1-10 µg/ml (1,000 times less that ascites). In both cases, antibody can be purified and concentrated for use in assays when particularly important MAbs have been characterised. At this stage, it is also important to elucidate the isotype of the MAb being studied. Mice produce mainly IgGl, IgG2a, IgG2b, IgG3, IgM or IgA antibodies. The isotype can have a significant influence on the functional properties of MAbs and also on the behaviour of the MAb in particular assays.
Topographical studies involve competition assays in which MAbs are labelled with enzyme or biotin and titrated against virus or a virus preparation of interest. The pretitrated reaction is then challenged by the addition of unlabelled MAb (including the homologous MAb). Significant interruption of the labelled MAb reaction can indicate that two MAbs react at similar locations on the virus. In the case of FMD viruses, care has to be taken in competition results due to the relatively small size of the virus, compared to the antibody molecule, since MAbs binding some distance from other sites can interfere with specific binding. However, this method is a simple but powerful tool for identifying important groups of MAb reactions and was used to determine the presence of four non-overlapping sites on the surface of FMD virus type O, three years before this was confirmed by more sophisticated and lengthy studies involving amino acid sequencing of escape mutants (see below). Figure 5 illustrates some of the principles involved in competition assays. 
Uses of monoclonal antibodies
After the initial phases of production and characterisation, MAbs may now be put to use. Data about MAbs tend to build up from studies using a variety of techniques and can be drawn from a number of different laboratories provided they are supplied with the same MAbs. Links between serological and molecular biological data will become clearer after consideration of sequencing data from field isolates and MAb escape mutants later in this paper, but for now, serological uses will be expanded. The fact that MAbs are single molecular structures is important when considering them as standardisable reagents. As workers are using exactly the same chemical, data from different sources are definitely comparable. This is not always true for data obtained with polyclonal antisera as part of any assay. Consequently, the use of MAbs avoids many of the problems associated with the heterogeneity of polyclonal responses. MAbs have a single affinity and react in the same way irrespective of the dilution, whereas dilution alters the avidity of polyclonal sera.
RAPID DISCRIMINATION OF FMD VIRUSES
Since MAbs are available which may be able to discriminate between isolates, rapid binding immunoassays can be performed to analyse the reaction of a large number of MAbs against a high number of viruses in a single test. The number of MAbs can be regarded as a panel. Again, the ELISA is highly suited to this purpose and has been widely used in many studies. Figure 6 shows a typical example of an ELISA for comparing viruses according to reaction with a number of MAbs. Viruses from tissue culture material are captured by a polyclonal rabbit serum. The MAbs are reacted at a single dilution (slight excess) and the binding of each MAb is compared to the binding with the homologous virus (the virus used to raise the MAbs). Thus, approximately the same weight of each virus is presented to the MAbs. Such studies provide a rapid measure of the epitope profiles of viruses. Identical reactions indicate that the same epitope is present; no reaction indicates major differences in the epitopes; and reduced reactions indicate similarities but not identity. Figure 7 shows a profile relating epitopes detected by MAbs against type SAT 2 viruses. This is a powerful method. However, it only partly elucidates the significance of antigenic differences. Figure 8 shows an analysis of nineteen type A FMD viruses by a large panel of MAbs from European and South American laboratories, where reactions are assessed as "maximal", "intermediate" or "none". As indicated earlier, it is the chemical composition (amino acid residues) which ultimately defines the properties of antigenic sites.
The amino acid structure of MAb-defined epitopes can also be determined by "sequencing". As the MAbs are neutralising MAb, escape mutants can be prepared and sequenced. These data can then be compared to data from the parental virus. Briefly, the parent FMD virus is mixed with a neutralising MAb. The parental virus stock contains mutants which vary in structure so that the MAb will not bind (hence not neutralise). However, the MAb does bind to the majority of the population, which is consequently neutralised. Incubation of infectious virus in the presence of the MAb therefore allows only mutants to grow. A mutant which has escaped neutralisation has thus been selected. A variety of escape mutants can be prepared where panels of neutralising MAbs are available, thus several epitopes involved in neutralisation can be examined. The avoidance of neutralisation involves amino acid changes in the epitope defined by the MAb. A single amino acid or a number of changes can stop binding. 
Antigenic profiling of type A foot and mouth disease viruses using monoclonal antibodies (MAbs) from various sources
Conversely, several changes within an epitope may only have the effect of reducing the binding energy of MAbs for epitope (affinity). The only way in which the effect of amino acid alterations can be assessed is to obtain sequencing data. However, there are some guidelines about certain substitutions and the effect they have on epitopes. The sequencing and comparison of MAb escape mutants leads to the defining of nonoverlapping epitopes. A stricter way to consider antigenic sites is to use the word "epitope" for the site on an agent studied, and "paratope" for the MAb defining that epitope. These terms would replace the terms "antigenic site" and "combining site", respectively. Where a number of MAbs react in the same topographical area but show slight differences in sequence, they can be regarded as defining an epitype. This method avoids the use of "antigenic site" to denote an area as well as a single highly-specific site defined by a MAb. In order to make this process clearer, an example can be given using data from the Institute for Animal Health (IAH), Pirbright Laboratory (United Kingdom). MAbs became available from the Istituto Zooprofilattico Sperimentale in Brescia (Italy) which neutralised Type Swiss FMD virus. Preliminary studies (ELISAs with different antigens, competition ELISAs, etc.) indicated that the panel consisted of at least three groups of different reactivity. MAb escape mutants were prepared using single MAbs from this panel to obtain single mutants. The MAb escape mutants were then subjected to further pressure from the other MAbs, in order to obtain double and triple mutants. The viruses were sequenced and comparative studies performed against the parental genome. Table I shows the amino acid changes associated with the MAb escape mutant groups. The groups were non-overlapping, as indicated by the ability to generate double and triple mutants. The residues detected were implicated as being involved in the neutralisation of virus by the interaction of antibodies. Three groups (antigenic sites/epitypes) which may be neutralised were confirmed. Another MAb was obtained which could neutralise the triple mutants, indicating that there was a further site possibly implicated in neutralisation. The triple mutants and parent virus were subjected to this MAb once more, and a fourth site was defined at the sequence level. Most recently, the quadrivalent mutant was neutralised by a MAb prepared in South America, thus defining a fifth site, which is being sequenced at present. At this point, one might wonder whether this process could continue indefinitely, leading to the development of a high number of epitypes. However, the mutants with five epitypic changes have lost their ability to be neutralised by polyclonal antisera produced after infection or vaccination with the parental virus. All the other mutants were neutralised by polyclonal sera, which indicated that there must be at least one more site by which the mutant could be bound. The discovery of the fifth site has eliminated the prospect of generating further mutants, excluding the possible development of MAbs which define another independent site (epitype). The data obtained by ELISA comparing the MAb binding (antigenic profiling) can be examined in the light of sequence data. Maximal binding of MAbs with two viruses indicates that they have conservation of sequence, while different degrees of binding reflect variation in sequence. This is valuable where a large number of isolates have to be examined since MAb ELISA data can be obtained rapidly from a large number of viruses and those showing differences with respect to the binding of MAbs can be selected for detailed sequence analysis. The power of using a MAb with defined sequence can be illustrated using work performed by Samuel and colleagues in 1988 (2), involving a MAb panel which reacted with amino acids in the VP1 region of type A 22 Iraq FMD virus (amino acids 142-155). Screening of different type A viruses with this panel revealed reactions with several isolates taken from many different parts of the world, which had been separated serologically by polyclonal serum assays. These viruses were sequenced and the A 22 sequence was identified in all the isolates previously identified by ELISA antigenic profiling, as shown in Figure 9 .
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Comparison of sequence data from foot and mouth disease viruses and identification of linear sequence by monoclonal antibodies (MAbs) Thus, combined ELISA/MAb screening of large numbers of isolates was able to identify potentially interesting candidates for sequencing. As more mutant groups are characterised, it should be possible to define MAbs according to their sequence origins. In this way, paratypic characterisation of isolates at the sequence level can be performed in binding assays. The data in Figure 8 include a number of amino acid residues associated with the reactivities of some of the MAbs (work from the Central Veterinary Institute in Lelystad, the Netherlands). This also illustrates a limitation in the use of MAbs, since a panel should contain MAbs which bind to as many different epitypes as possible. Thus, it is important that the production and characterisation of MAbs continue, in order to build up data to allow significant conclusions to be made where similarities and differences are shown, and to allow assessment of the epidemiological significance of the epitopes detected. It is very important that data on sequencing mutants and MAbs themselves are freely exchanged to allow laboratories to perform more extensive characterisations. This approach is being encouraged by the FAO/OIE Standing Committee on the Standardisation and Control of FMD in Europe. Exchange of data and reagents has commenced and is being extended, as other laboratories in the world gain expertise and resources.
With FMD virus, one can go further than defining antigenic sites at the sequence level, since the virus can be crystallised and X-ray detraction data obtained in order that the three-dimensional atomic structure may be visualised. This is a very specialised and time-consuming approach, but it does allow a connection to be made between sequence data and structure. Thus the parental type O virus has been crystallographed along with many of the mutants. The amino acids defined by the MAbs can now be examined at the structural level and the implications assessed. In addition to the theoretical interest, important considerations can be made with regard to the formulation of vaccines, the interaction of epitopes with cell receptors, the design of peptide blocking drugs and chemical stability.
PEPTIDES
A knowledge of the sequencing data for a particular agent can lead to the use of peptides as antigens in specific immunoassays. Certain of the anti-FMD virus MAbs quoted above define non-conformational sites and react with a linear run of amino acids. Such sites are not affected if antigens are denatured by boiling agents such as SDS or mercaptoethanol. MAbs which define a specific region can therefore be adapted to relatively simple binding assays to measure antibody against a particular site or to compare other agents for a particular antigenic reaction. Other, more sophisticated techniques are available to define important peptide sequences. One of these is Pepskan analysis, whereby amino acids are added in sequence to a solid phase and reactions with antibody determined. Many combinations of amino acids can be overlapped and compared, so that the reactivity of sera and MAbs can be defined in binding assays. This technique can be used to define complex linear antigenic sites where the sequence is known and can be translated into peptides by chemical synthesis. Once defined, the critical sequence (often three to eight amino acids) can be synthesised in large quantities and used for assays or as a therapeutic agent. A totally defined test system comprising MAb and peptide is therefore available; such reagents thus provide a potential for the perfect standardisation of assays. This is far from being a remote hope, as there is often a great deal of sequence information available for the majority of important disease agents. There has also been great interest in the use of peptides as vaccines, leading to the manufacture of totally safe (non-infectious), chemicallysynthesised reagents. In the case of FMD viruses, there are regions on the capsid which form a linear antigenic site intimately involved with neutralisation. MAbs have identified the amino acids involved on this site, and peptides with this structure have been synthesised. The peptides induce protection in guinea-pigs but, unfortunately, are less effective in cattle, where it is hoped they could be of some practical use. However, this work has led to a deeper insight into the requirements for the production of active peptide formulations, and immunological studies have been initiated to help understand T cell binding sites in association with peptides.
CONCLUSIONS
Monoclonal antibodies can provide a link between the chemical and antigenic structure of epitopes.
Detailed evaluation of sites is possible where escape mutants can be produced, as with those which neutralise viruses. Diagnosis can be greatly improved by an understanding of the exact reaction of MAbs, and agents can be identified by the presence or absence of specific amino acid residues by relatively simple binding assays. The exploitation of panels of MAbs for the antigenic profiling of a large number of isolates can be extremely useful in identifying agents which need to be sequenced. This is vital in epidemiological studies, as well as in cases where definitive identification of the origin of infection is required. MAbs are also vital for the identification of sites which can be studied in terms of their function. The use of crystallographic X-ray techniques allows full exploitation of the MAb link between the linear, chemical and the three-dimensional, structural aspects of epitopes. 
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